Arizona State Retirement System Has $77,000 Stock Position in Cogent Biosciences, Inc. (NASDAQ:COGT)

Arizona State Retirement System lowered its position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT) by 14.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,141 shares of the technology company’s stock after selling 2,305 shares during the period. Arizona State Retirement System’s holdings in Cogent Biosciences were worth $77,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in COGT. SG Americas Securities LLC raised its stake in Cogent Biosciences by 169.4% in the third quarter. SG Americas Securities LLC now owns 104,722 shares of the technology company’s stock valued at $1,021,000 after purchasing an additional 65,843 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Cogent Biosciences by 15.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 288,207 shares of the technology company’s stock valued at $2,810,000 after buying an additional 39,491 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Cogent Biosciences by 29.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,328 shares of the technology company’s stock valued at $110,000 after buying an additional 2,571 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Cogent Biosciences by 15.2% during the 3rd quarter. Principal Financial Group Inc. now owns 21,267 shares of the technology company’s stock worth $207,000 after acquiring an additional 2,803 shares during the period. Finally, Fox Run Management L.L.C. acquired a new stake in shares of Cogent Biosciences during the 3rd quarter worth approximately $99,000.

Analysts Set New Price Targets

Several research analysts have commented on COGT shares. Needham & Company LLC restated a “buy” rating and set a $18.00 price objective on shares of Cogent Biosciences in a research report on Monday, February 26th. Leerink Partnrs restated an “outperform” rating on shares of Cogent Biosciences in a research report on Thursday, February 22nd. Wedbush lifted their target price on Cogent Biosciences from $5.00 to $10.00 and gave the company a “neutral” rating in a research report on Friday, February 23rd. JPMorgan Chase & Co. increased their target price on shares of Cogent Biosciences from $18.00 to $20.00 and gave the stock an “overweight” rating in a report on Tuesday, February 27th. Finally, Citigroup lifted their price target on shares of Cogent Biosciences from $11.00 to $13.00 and gave the company a “buy” rating in a report on Monday, February 26th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $13.67.

Cogent Biosciences Trading Up 6.1 %

Cogent Biosciences stock opened at $7.12 on Tuesday. The stock has a 50-day moving average price of $7.01 and a two-hundred day moving average price of $6.81. Cogent Biosciences, Inc. has a 12 month low of $3.67 and a 12 month high of $13.50. The company has a market capitalization of $680.74 million, a PE ratio of -2.97 and a beta of 1.51.

Cogent Biosciences (NASDAQ:COGT) last released its quarterly earnings data on Monday, February 26th. The technology company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.08). As a group, analysts predict that Cogent Biosciences, Inc. will post -1.89 earnings per share for the current fiscal year.

Cogent Biosciences Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.